DOCSLIB.ORG

Differential Expression of Neuregulin-1 Isoforms and Downregulation of Erbin Are Associated with Erb B2 Receptor Activation in Diabetic Peripheral Neuropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Expression of Neuregulin-1 Isoforms and Downregulation of Erbin Are Associated with Erb B2 Receptor Activation in Diabetic Peripheral Neuropathy Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy By Pan Pan Submitted to the graduate degree program in Pharmacology and Toxicology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ______________________________ Rick T. Dobrowsky, Ph.D., Chairperson _______________________________ Jeff Staudinger, Ph.D. _______________________________ Alexander Moise, Ph.D. _______________________________ Honglian Shi. Ph.D. ________________________________ Brian Ackley, Ph.D. Date Defended: April 18th The Dissertation Committee for Pan Pan certifies that this is the approved version of the following dissertation: Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy By Pan Pan _______________________________ Rick T. Dobrowsky, Ph.D., Chairperson th Date approved: April 18 ii Table of Contents Table of Contents ......................................................................................................................... iii Abstract ......................................................................................................................................... vi Acknowledgements ..................................................................................................................... vii List of Tables and Figures ........................................................................................................... ix List of Abbreviations .................................................................................................................. xii Chapter 1: Introduction ............................................................................................................... 1 1.1. Overview of Diabetes Mellitus ........................................................................................ 1 1.1.1. Diabetes Mellitus .......................................................................................................... 1 1.1.2. Diagnostic Criteria of Diabetes Mellitus ...................................................................... 2 1.1.3. Classification and Clinical Features of Diabetes Mellitus............................................ 4 Type 1 Diabetes Mellitus ......................................................................................................... 5 Type 2 Diabetes Mellitus ......................................................................................................... 8 Gestational Diabetes and Other Sub-types ........................................................................... 11 1.1.4. The Action of Insulin .................................................................................................. 12 1.1.5. Mitochondrial Dysfunction in β-cell Death ................................................................ 14 1.2. Diabetic Complications .................................................................................................. 17 1.2.1. Diabetic Retinopathy .................................................................................................. 18 1.2.2. Diabetic Nephropathy ................................................................................................. 21 1.2.3. Cardiovascular Disease............................................................................................... 24 1.3. Diabetic Neuropathy ...................................................................................................... 25 1.3.1. Classification and Clinical Features ........................................................................... 25 Diabetic Autonomic Neuropathy (DAN) ............................................................................... 26 Diabetic Sensorimotor Polyneuropathy (DPN) ..................................................................... 27 1.3.2. Animal Models of Diabetic Peripheral Neuropathy ................................................... 30 Type 1 Diabetic Models ......................................................................................................... 30 Type 2 Diabetic Models ......................................................................................................... 32 1.3.3. Pathology, Current Management and Treatments ...................................................... 32 Advanced Glycation End-products Pathway ......................................................................... 33 Polyol Pathway ...................................................................................................................... 34 iii Protein Kinase C Pathway .................................................................................................... 35 Inflammation Pathway........................................................................................................... 36 Oxidative Stress and Mitochondrial Dysfunction .................................................................. 37 1.4. Growth Factors in Peripheral Nervous System .............................................................. 39 1.4.1. Neurotrophin Family .................................................................................................. 40 Nerve Growth Factor ............................................................................................................ 41 Brain-derived Neurotrophic Factor and Neurotrophin-3 ..................................................... 43 1.4.2. Insulin-like Growth Factor Family ............................................................................. 44 1.5. Neuregulin-Erb B Signaling in Peripheral Nervous System .......................................... 46 1.5.1. Ligand Neuregulin-1 Family and Erb B Receptors .................................................... 46 1.5.2. Neuregulin-Erb B Signaling in Peripheral Nerve Development ................................ 49 1.5.3. Neuregulin-Erb B Signaling in Nerve Injury ............................................................. 53 1.5.4. Adapter Protein Erb B2-Interacting Protein ............................................................... 54 1.6. Dissertation Hypothesis .................................................................................................. 55 Chapter 2: Materials and Methods ........................................................................................... 57 2.1. Materials ......................................................................................................................... 57 2.1.1. Animals ....................................................................................................................... 57 2.1.2. Antibodies ................................................................................................................... 57 2.1.3. Peptide Competition Assay ........................................................................................ 58 2.1.4. Reagents...................................................................................................................... 59 2.2. Methods .......................................................................................................................... 60 2.2.1. Induction of Diabetes and Measurement of Fasting Blood Glucose (FBG) ............... 60 2.2.2. Measurement of Glycated Hemoglobin ...................................................................... 60 2.2.3. Assessments of Sensory Sensitivity ........................................................................... 60 Thermal Sensitivity ................................................................................................................ 60 Mechanical Sensitivity ........................................................................................................... 61 2.2.4. Nerve Conduction Velocity ........................................................................................ 61 Motor Nerve Conduction Velocity ......................................................................................... 62 Sensory Nerve Conduction Velocity ...................................................................................... 63 2.2.5. Erlotinib Administration ............................................................................................. 64 2.2.6. Immunohistochemistry of Footpad Tissue ................................................................. 64 iv 2.2.7. Immunoblot Analysis ................................................................................................. 65 2.2.8. Erbin-shRNA Lentivirus Preparation and Infection ................................................... 66 2.2.9. Preparation of Myelinated Mouse DRG/Schwann Cell Co-cultures .......................... 67 2.2.10. Preparation of Schwann Cell Cultures........................................................................ 67 2.2.11. Measurement of Mitochondrial Respiration ............................................................... 68 2.2.12. Mitochondrial Fraction ............................................................................................... 69 2.2.13. Statistical Analysis ..................................................................................................... 69 Chapter 3: Dysfunction of Neuregulin-Erb B2 Ligand-Receptor Signaling Pathway in Diabetic Peripheral Neuropathy ...............................................................................................
Load more

Recommended publications
  • Signalling Between Microvascular Endothelium and Cardiomyocytes Through Neuregulin Downloaded From
    Cardiovascular Research (2014) 102, 194–204 SPOTLIGHT REVIEW doi:10.1093/cvr/cvu021 Signalling between microvascular endothelium and cardiomyocytes through neuregulin Downloaded from Emily M. Parodi and Bernhard Kuhn* Harvard Medical School, Boston Children’s Hospital, 300 Longwood Avenue, Enders Building, Room 1212, Brookline, MA 02115, USA Received 21 October 2013; revised 23 December 2013; accepted 10 January 2014; online publish-ahead-of-print 29 January 2014 http://cardiovascres.oxfordjournals.org/ Heterocellular communication in the heart is an important mechanism for matching circulatory demands with cardiac structure and function, and neuregulins (Nrgs) play an important role in transducing this signal between the hearts’ vasculature and musculature. Here, we review the current knowledge regarding Nrgs, explaining their roles in transducing signals between the heart’s microvasculature and cardiomyocytes. We highlight intriguing areas being investigated for developing new, Nrg-mediated strategies to heal the heart in acquired and congenital heart diseases, and note avenues for future research. ----------------------------------------------------------------------------------------------------------------------------------------------------------- Keywords Neuregulin Heart Heterocellular communication ErbB -----------------------------------------------------------------------------------------------------------------------------------------------------------† † † This article is part of the Spotlight Issue on: Heterocellular signalling
    [Show full text]
  • Stress Hormones Trk Neurons Into Survival
    RESEA r CH HIGHLIGHTS M olec U lar ne U roscience Similar to the in vivo experi- ments, Dex treatment of cultured neurons did not increase levels of Stress hormones Trk BDNF, NGF or NT3, suggesting that the neuroprotective effect of Dex is independent of neurotrophin release. neurons into survival Administration of an inhibitor of the PI3K–AKT pathway abolished Dex- which adult neurogenesis occurs. mediated neuroprotection, whereas Surprisingly, Dex administration did adding a Trk inhibitor only reduced not alter levels of the neurotrophins it; thus, glucocorticoids might also nerve growth factor (NGF), brain- stimulate the PI3K–AKT pathway derived neurotrophic factor (BDNF) through a route that does not involve and neurotrophin 3 (NT3) in the hip- TrkB phosphorylation. pocampus or in the parietal cortex, The mechanism by which gluco- indicating that the phosphorylation corticoids activate Trks is unknown of TrkB by glucocorticoids did not but probably involves the gluco- require increased neurotrophin corticoid receptor, as addition of a production. glucocorticoid receptor antagonist Phosphorylated Trks are activated abolished Dex-mediated neuropro- tyrosine kinases, which can phospho- tection. The glucocorticoid effects rylate other proteins. Thus, adding were slow and lasted for several Glucocorticoids have a bad reputa- Dex or BDNF (the main ligand for hours, which is suggestive of genomic tion. However, although these stress the TrkB receptor) to cortical slices actions. Indeed, Trk activation by hormones can be neurotoxic in activated TrkB and phosphorylated Dex could be abolished by actinomy- high levels, they are also required the intracellular signalling molecules cin D and cycloheximine, inhibitors for neuronal survival, and they AKT, phospholipase Cγ (PLCγ) and of transcription and translation, promote neuronal growth and dif- extracellular signal-regulated kinase respectively.
    [Show full text]
  • Differential Effects of Dehydroepiandrosterone and Testosterone in Prostate and Colon Cancer Cell Apoptosis: the Role of Nerve Growth Factor (NGF) Receptors
    DHEA e testosterona e apoptose no câncer de próstata e de colon, papel do NGF – fator de crescimento neural. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Anagnostopoulou V1, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, Gravanis A, Charalampopoulos I, Stournaras C. Endocrinology. 2013 Jul;154(7):2446-56. Author information 1 Department of Biochemistry, University of Crete Medical School, GR-71003 Heraklion, Greece. Abstract Tumor growth is fostered by inhibition of cell death, which involves the receptiveness of tumor to growth factors and hormones. We have recently shown that testosterone exerts proapoptotic effects in prostate and colon cancer cells through a membrane-initiated mechanism. In addition, we have recently reported that dehydroepiandrosterone (DHEA) can control cell fate, activating nerve growth factor (NGF) receptors, namely tropomyosin-related kinase (Trk)A and p75 neurotrophin receptor, in primary neurons and in PC12 tumoral cells. NGF was recently involved in cancer cell proliferation and apoptosis. In the present study, we explored the cross talk between androgens (testosterone and DHEA) and NGF in regulating apoptosis of prostate and colon cancer cells. DHEA and NGF strongly blunted serum deprivation-induced apoptosis, whereas testosterone induced apoptosis of both cancer cell lines. The antiapoptotic effect of both DHEA and NGF was completely reversed by testosterone. In line with this, DHEA or NGF up-regulated, whereas testosterone down- regulated, the expression of TrkA receptor. The effects of androgens were abolished in both cell lines in the presence of TrkA inhibitor. DHEA induced the phosphorylation of TrkA and the interaction of p75 neurotrophin receptor with its effectors, Rho protein GDP dissociation inhibitor and receptor interacting serine/threonine-protein kinase 2.
    [Show full text]
  • Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung
    ORIGINAL ARTICLE Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues Kuniko Sunami, MD,a,g Koh Furuta, MD, PhD,b Koji Tsuta, MD, PhD,c Shinji Sasada, MD, PhD,d Takehiro Izumo, MD, PhD,d Takashi Nakaoku, MD,a Yoko Shimada, MFSc,a Motonobu Saito, MD, PhD,a Hiroshi Nokihara, MD, PhD,e Shun-ichi Watanabe, MD, PhD,f Yuichiro Ohe, MD, PhD,e,g Takashi Kohno, PhDa,* aDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan bDivision of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan cDivision of Pathology, National Cancer Center Research Institute, Tokyo, Japan dDepartment of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Research Institute, Tokyo, Japan eDepartment of Thoracic Oncology, National Cancer Center Research Institute, Tokyo, Japan fDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan gCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan Received 31 July 2015; revised 23 September 2015; accepted 13 October 2015 ABSTRACT detected oncogenic fusions in bronchial lavage fluid and transbronchial biopsy samples. Introduction: Fusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret proto-oncogene (RET), ROS Conclusions: The MC assay allows multiplex detection of proto-oncogene 1, receptor tyrosine kinase gene (ROS1), B- oncogenic fusion and exon-skipped transcripts in tumor Raf proto-oncogene, serine/threonine kinase gene (BRAF), samples, including in formalin-fixed paraffin-embedded and neuregulin 1 gene (NRG1) and intronic MMNG HOS samples obtained in the clinic. Transforming gene (MET) mutations are druggable onco- Ó 2015 International Association for the Study of Lung gene alterations in lung adenocarcinoma that cause Cancer.
    [Show full text]
  • Wnt/Β-Catenin Signaling Regulates Regeneration in Diverse Tissues of the Zebrafish
    Wnt/β-catenin Signaling Regulates Regeneration in Diverse Tissues of the Zebrafish Nicholas Stockton Strand A dissertation Submitted in partial fulfillment of the Requirements for the degree of Doctor of Philosophy University of Washington 2016 Reading Committee: Randall Moon, Chair Neil Nathanson Ronald Kwon Program Authorized to Offer Degree: Pharmacology ©Copyright 2016 Nicholas Stockton Strand University of Washington Abstract Wnt/β-catenin Signaling Regulates Regeneration in Diverse Tissues of the Zebrafish Nicholas Stockton Strand Chair of the Supervisory Committee: Professor Randall T Moon Department of Pharmacology The ability to regenerate tissue after injury is limited by species, tissue type, and age of the organism. Understanding the mechanisms of endogenous regeneration provides greater insight into this remarkable biological process while also offering up potential therapeutic targets for promoting regeneration in humans. The Wnt/β-catenin signaling pathway has been implicated in zebrafish regeneration, including the fin and nervous system. The body of work presented here expands upon the role of Wnt/β-catenin signaling in regeneration, characterizing roles for Wnt/β-catenin signaling in multiple tissues. We show that cholinergic signaling is required for blastema formation and Wnt/β-catenin signaling initiation in the caudal fin, and that overexpression of Wnt/β-catenin ligand is sufficient to rescue blastema formation in fins lacking cholinergic activity. Next, we characterized the glial response to Wnt/β-catenin signaling after spinal cord injury, demonstrating that Wnt/β-catenin signaling is necessary for recovery of motor function and the formation of bipolar glia after spinal cord injury. Lastly, we defined a role for Wnt/β-catenin signaling in heart regeneration, showing that cardiomyocyte proliferation is regulated by Wnt/β-catenin signaling.
    [Show full text]
  • Human NT4 / Neurotrophin 5 ELISA Kit (ARG81416)
    Product datasheet [email protected] ARG81416 Package: 96 wells Human NT4 / Neurotrophin 5 ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG81416-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG81416-002 Standard 2 X 10 ng/vial 4°C ARG81416-003 Standard/Sample 30 ml (Ready to use) 4°C diluent ARG81416-004 Antibody conjugate 1 vial (100 µl) 4°C concentrate (100X) ARG81416-005 Antibody diluent 12 ml (Ready to use) 4°C buffer ARG81416-006 HRP-Streptavidin 1 vial (100 µl) 4°C concentrate (100X) ARG81416-007 HRP-Streptavidin 12 ml (Ready to use) 4°C diluent buffer ARG81416-008 25X Wash buffer 20 ml 4°C ARG81416-009 TMB substrate 10 ml (Ready to use) 4°C (Protect from light) ARG81416-010 STOP solution 10 ml (Ready to use) 4°C ARG81416-011 Plate sealer 4 strips Room temperature Summary Product Description ARG81416 Human NT4 / Neurotrophin 5 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human NT4 / Neurotrophin 5 in serum and cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Specificity There is no detectable cross-reactivity with other relevant proteins. Target Name NT4 / Neurotrophin 5 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 15.6 pg/ml Sample Type Serum and cell culture supernatants. Standard Range 31.2 - 2000 pg/ml Sample Volume 100 µl www.arigobio.com 1/2 Precision Intra-Assay CV: 6.6% Inter-Assay CV: 7.7% Alternate Names NTF5; NT-4/5; NT5; NT4; GLC10; GLC1O; NT-5; NT-4; Neurotrophin-4; Neurotrophin-5; Neutrophic factor 4 Application Instructions Assay Time ~ 5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • RET Controls Sympathetic Innervation
    Development 128, 3963-3974 (2001) 3963 Printed in Great Britain © The Company of Biologists Limited 2001 DEV8811 RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons Hideki Enomoto1, Peter A. Crawford1, Alexander Gorodinsky1, Robert O. Heuckeroth2,3, Eugene M. Johnson, Jr3 and Jeffrey Milbrandt1,* 1Departments of Pathology and Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8118, St Louis, MO 63110, USA 2Department of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, Box 8116, St Louis, MO 63110, USA 3Department of Molecular Biology and Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8113, St Louis, MO 63110, USA *Author for correspondence (e-mail: [email protected]) Accepted 26 July 2001 SUMMARY Sympathetic axons use blood vessels as an intermediate trunks and accelerated cell death of sympathetic neurons path to reach their final target tissues. The initial contact later in development. Artemin is expressed in blood vessels between differentiating sympathetic neurons and blood during periods of early sympathetic differentiation, and vessels occurs following the primary sympathetic chain can promote and attract axonal growth of the sympathetic formation, where precursors of sympathetic neurons ganglion in vitro. This analysis identifies RET and artemin migrate and project axons along or toward blood vessels. as central regulators of early sympathetic innervation. We demonstrate
    [Show full text]
  • Promoting Myelin Repair and Return of Function in Multiple Sclerosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 585 (2011) 3813–3820 journal homepage: www.FEBSLetters.org Review Promoting myelin repair and return of function in multiple sclerosis Jingya Zhang a,b,c, Elisabeth G. Kramer a,b,c, Linnea Asp a,b,c, Dipankar J. Dutta a,b,c, Kristina Navrazhina a,b,c, Trinh Pham a,b,c, John N. Mariani a,b,c, Azeb Tadesse Argaw a,b,c, Carmen V. Melendez-Vasquez d, ⇑ Gareth R. John a,b,c, a Corinne Goldsmith Dickinson Center for MS, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA b Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA c Friedman Brain Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA d Department of Biological Sciences, Hunter College, 695 Park Avenue, New York, NY 10065, USA article info abstract Article history: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. Conduction block in Received 7 July 2011 demyelinated axons underlies early neurological symptoms, but axonal transection and neuronal Revised 8 August 2011 loss are believed to be responsible for more permanent chronic deficits. Several therapies are Accepted 9 August 2011 approved for treatment of relapsing-remitting MS, all of which are immunoregulatory and clinically Available online 18 August 2011 proven to reduce the rate of lesion formation and exacerbation. However, existing approaches are Edited by Richard Williams, Alexander only partially effective in preventing the onset of disability in MS patients, and novel treatments Flügel and Wilhelm Just to protect myelin-producing oligodendrocytes and enhance myelin repair may improve long-term outcomes.
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Angiocrine Endothelium: from Physiology to Cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3
    Pasquier et al. J Transl Med (2020) 18:52 https://doi.org/10.1186/s12967-020-02244-9 Journal of Translational Medicine REVIEW Open Access Angiocrine endothelium: from physiology to cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3 Abstract The concept of cancer as a cell-autonomous disease has been challenged by the wealth of knowledge gathered in the past decades on the importance of tumor microenvironment (TM) in cancer progression and metastasis. The sig- nifcance of endothelial cells (ECs) in this scenario was initially attributed to their role in vasculogenesis and angiogen- esis that is critical for tumor initiation and growth. Nevertheless, the identifcation of endothelial-derived angiocrine factors illustrated an alternative non-angiogenic function of ECs contributing to both physiological and pathological tissue development. Gene expression profling studies have demonstrated distinctive expression patterns in tumor- associated endothelial cells that imply a bilateral crosstalk between tumor and its endothelium. Recently, some of the molecular determinants of this reciprocal interaction have been identifed which are considered as potential targets for developing novel anti-angiocrine therapeutic strategies. Keywords: Angiocrine, Endothelium, Cancer, Cancer microenvironment, Angiogenesis Introduction of blood vessels in initiation of tumor growth and stated Metastatic disease accounts for about 90% of patient that in the absence of such angiogenesis, tumors can- mortality. Te difculty in controlling and eradicating not expand their mass or display a metastatic phenotype metastasis might be related to the heterotypic interaction [7]. Based on this theory, many investigators assumed of tumor and its microenvironment [1].
    [Show full text]
  • Expression of the Neurotrophic Tyrosine Kinase Receptors, Ntrk1 and Ntrk2a, Precedes Expression of Other Ntrk Genes in Embryonic Zebrafish
    Expression of the neurotrophic tyrosine kinase receptors, ntrk1 and ntrk2a, precedes expression of other ntrk genes in embryonic zebrafish Katie Hahn, Paul Manuel and Cortney Bouldin Department of Biology, Appalachian State University, Boone, NC, USA ABSTRACT Background: The neurotrophic tyrosine kinase receptor (Ntrk) gene family plays a critical role in the survival of somatosensory neurons. Most vertebrates have three Ntrk genes each of which encode a Trk receptor: TrkA, TrkB, or TrkC. The function of the Trk receptors is modulated by the p75 neurotrophin receptors (NTRs). Five ntrk genes and one p75 NTR gene (ngfrb) have been discovered in zebrafish. To date, the expression of these genes in the initial stages of neuron specification have not been investigated. Purpose: The present work used whole mount in situ hybridization to analyze expression of the five ntrk genes and ngfrb in zebrafish at a timepoint when the first sensory neurons of the zebrafish body are being established (16.5 hpf). Because expression of multiple genes were not found at this time point, we also checked expression at 24 hpf to ensure the functionality of our six probes. Results: At 16.5 hpf, we found tissue specific expression of ntrk1 in cranial ganglia, and tissue specific expression of ntrk2a in cranial ganglia and in the spinal cord. Other genes analyzed at 16.5 hpf were either diffuse or not detected. At 24 hpf, we found expression of both ntrk1 and ntrk2a in the spinal cord as well as in multiple cranial ganglia, and we identified ngfrb expression in cranial ganglia at 24 hpf.
    [Show full text]
  • The Impact of Neurotrophin-3 on the Dorsal Root Transitional Zone Following Injury
    Spinal Cord (2008) 46, 804–810 & 2008 International Spinal Cord Society All rights reserved 1362-4393/08 $32.00 www.nature.com/sc ORIGINAL ARTICLE The impact of neurotrophin-3 on the dorsal root transitional zone following injury AT Hanna-Mitchell1, D O’Leary1, MS Mobarak1, MS Ramer2, SB McMahon3, JV Priestley4, EN Kozlova5, H Aldskogius5, P Dockery6 and JP Fraher1 1Department of Anatomy/Neuroscience, BioSciences Institute, National University of Ireland, Cork, Ireland; 2CORD (Collaboration on Repair Discoveries), University of British Columbia, Vancouver, Canada; 3Neurorestoration Group, Wolfson Centre for Age Related Diseases, Kings College London, London, UK; 4Neuroscience Centre, Institute of Cell and Molecular Science, Queen Mary University of London, London, UK; 5Department of Neuroscience, Biomedical Centre, Uppsala University, Uppsala, Sweden and 6Department of Anatomy, National University of Ireland, Galway, Ireland Study design: Morphological and Stereological assessment of the dorsal root transitional zone (DRTZ) following complete crush injury, using light microscopy (LM) and transmission electron microscopy (TEM). Objectives: To assess the effect of exogenous neurotrophin-3 (NT-3) on the response of glial cells and axons to dorsal root damage. Setting: Department of Anatomy, University College Cork, Ireland and Department of Physiology, UMDS, University of London, UK. Methods: Cervical roots (C6-8) from rats which had undergone dorsal root crush axotomy 1 week earlier, in the presence (n ¼ 3) and absence (n ¼ 3) of NT-3, were processed for LM and TEM. Results: Unmyelinated axon number and size was greater in the DRTZ proximal (Central Nervous System; CNS) and distal (Peripheral Nervous System; PNS) compartments of NT-3-treated tissue.
    [Show full text]